PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Keymed Biosciences Inc (2162.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG5252B1023
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$9.76B
Total Revenue (TTM)HK$327.12M
Gross Profit (TTM)HK$312.11M
Year RangeHK$26.60 - HK$64.80
Target PriceHK$61.62

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Keymed Biosciences Inc

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Keymed Biosciences Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%2024FebruaryMarchAprilMayJune
-49.12%
27.08%
2162.HK (Keymed Biosciences Inc)
Benchmark (^GSPC)

S&P 500

Returns By Period

Keymed Biosciences Inc had a return of -29.53% year-to-date (YTD) and -17.03% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-29.53%14.57%
1 month-4.42%2.97%
6 months-24.54%14.93%
1 year-17.03%24.71%
5 years (annualized)N/A13.14%
10 years (annualized)N/A10.88%

Monthly Returns

The table below presents the monthly returns of 2162.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-37.07%10.84%-1.02%0.15%-5.15%-29.53%
202331.76%-6.25%-7.94%7.76%-34.80%0.37%34.35%-2.91%-6.47%16.63%-3.52%-12.56%-3.73%
2022-23.03%8.52%-24.43%6.70%2.16%39.83%-7.58%15.25%1.28%26.40%12.33%0.89%48.69%
2021-8.60%-18.02%0.98%-22.25%18.25%-27.48%-49.56%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 2162.HK is 39, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.


The Risk-Adjusted Performance Rank of 2162.HK is 3939
2162.HK (Keymed Biosciences Inc)
The Sharpe Ratio Rank of 2162.HK is 3838Sharpe Ratio Rank
The Sortino Ratio Rank of 2162.HK is 4040Sortino Ratio Rank
The Omega Ratio Rank of 2162.HK is 4040Omega Ratio Rank
The Calmar Ratio Rank of 2162.HK is 3636Calmar Ratio Rank
The Martin Ratio Rank of 2162.HK is 4040Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Keymed Biosciences Inc (2162.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


2162.HK
Sharpe ratio
The chart of Sharpe ratio for 2162.HK, currently valued at -0.21, compared to the broader market-2.00-1.000.001.002.003.00-0.21
Sortino ratio
The chart of Sortino ratio for 2162.HK, currently valued at 0.14, compared to the broader market-4.00-2.000.002.004.006.000.14
Omega ratio
The chart of Omega ratio for 2162.HK, currently valued at 1.02, compared to the broader market0.501.001.502.001.02
Calmar ratio
The chart of Calmar ratio for 2162.HK, currently valued at -0.21, compared to the broader market0.002.004.006.00-0.21
Martin ratio
The chart of Martin ratio for 2162.HK, currently valued at -0.43, compared to the broader market0.0010.0020.00-0.43
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.24, compared to the broader market-2.00-1.000.001.002.003.002.24
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.16, compared to the broader market-4.00-2.000.002.004.006.003.16
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.39, compared to the broader market0.501.001.502.001.39
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.78, compared to the broader market0.002.004.006.001.78
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 8.36, compared to the broader market0.0010.0020.008.36

Sharpe Ratio

The current Keymed Biosciences Inc Sharpe ratio is -0.21. This value is calculated based on the past 1 year of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Keymed Biosciences Inc with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.002024FebruaryMarchAprilMayJune
-0.21
2.21
2162.HK (Keymed Biosciences Inc)
Benchmark (^GSPC)

Dividends

Dividend History


Keymed Biosciences Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-70.00%-60.00%-50.00%-40.00%-30.00%-20.00%-10.00%0.00%2024FebruaryMarchAprilMayJune
-56.31%
-0.43%
2162.HK (Keymed Biosciences Inc)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Keymed Biosciences Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Keymed Biosciences Inc was 74.71%, occurring on Mar 21, 2022. Recovery took 212 trading sessions.

The current Keymed Biosciences Inc drawdown is 56.31%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-74.71%Jul 14, 2021171Mar 21, 2022212Feb 1, 2023383
-65.34%Feb 3, 2023298Apr 19, 2024

Volatility

Volatility Chart

The current Keymed Biosciences Inc volatility is 15.00%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


5.00%10.00%15.00%20.00%25.00%2024FebruaryMarchAprilMayJune
15.00%
2.34%
2162.HK (Keymed Biosciences Inc)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Keymed Biosciences Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items